10.6084/m9.figshare.8636738.v1
Anthony Markham
Anthony
Markham
Susan J. Keam
Susan J.
Keam
Camrelizumab: First Global Approval
Adis Journals
2019
Camrelizumab
PD-1 inhibitor
review
Adis Insight Report
Hodgkin lymphoma
cancer
AiRuiKa™
2019-07-17 00:50:05
Online resource
https://adisjournals.figshare.com/articles/online_resource/Camrelizumab_First_Global_Approval/8636738
<p><b>Compliance
with Ethical Standards</b><br></p><p><b><br></b></p><p><b>Funding:</b> The preparation of this review was not supported
by any external funding.</p><p>
<b>Conflicts
of interest:<i> </i> </b>During
the peer review process the manufacturer of the agent under review was offered
an opportunity to comment on the article. Changes resulting from any comments
received were made by the authors on the basis of scientific completeness and
accuracy. A. Markham, a
contracted employee of Adis International Ltd/Springer Nature, and Susan Keam, a salaried employees of Adis International Ltd/Springer Nature are responsible for the article content and
declares no relevant conflicts of interest.</p><p>Additional
information about this Adis Drug Review can be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews"><b>here</b></a></p><div><div><br></div></div><div>Abstract</div><div><p>Camrelizumab (AiRuiKa™),
a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui
Medicine Co. Ltd, recently received conditional approval in China for the
treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is
also being investigated as a treatment for various other malignancies,
including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal
junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and
non-squamous, non-small-cell lung cancer. This article summarizes the
milestones in the development of camrelizumab leading to this first approval
for classical Hodgkin lymphoma.</p><br></div><div><p>© Springer
Nature Switzerland AG 2019</p><br></div>